Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088621 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00088621: Completed Phase 2 study, sponsored by Sumitomo Pharma America.
NCT00088621 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088621, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Interventions
- DRUG Lurasidone 80mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00088621 record still lists
NCT00088621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 1 intervention - of which Lurasidone 80mg tablet is the first listed.
NCT00088621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088621 about?
NCT00088621 is a clinical study titled "A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia". A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
What is the current status of trial NCT00088621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2004-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00088621?
The interventions under investigation include: Lurasidone 80mg tablet (DRUG).
Who is sponsoring clinical trial NCT00088621?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088621's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia